Nagahiro George Saijo

Nagahiro George Saijo's AcademicInfluence.com Rankings

Philosophy

#6094

World Rank

#9067

Historical Rank

Logic

#3286

World Rank

#4419

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Nagahiro George Saijo's Degrees

PhD Pharmaceutical Sciences University of Tokyo
Doctorate Medicine University of Tokyo

Why Is Nagahiro George Saijo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nagahiro George Saijo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. (2009) (6176)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer (2016) (2632)
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). (2011) (1443)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. (2002) (1305)
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. (2002) (617)
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. (2006) (610)
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. (1991) (431)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. (2010) (418)
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. (2008) (359)
Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer (2008) (355)
Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. (1991) (273)
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 (2007) (269)
UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer (2004) (262)
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. (2010) (208)
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer (2012) (205)
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. (1990) (197)
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). (2012) (195)
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. (2009) (185)
Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. (2006) (180)
Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. (1990) (177)
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. (2004) (177)
The development and clinical use of a beam ON-LINE PET system mounted on a rotating gantry port in proton therapy. (2008) (175)
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. (2012) (175)
Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. (2008) (174)
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 (2007) (173)
Disparities in gastric cancer chemotherapy between the East and West. (2006) (169)
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. (1996) (162)
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. (2006) (162)
Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population (2004) (159)
Anticancer drug discovery and development throughout the world. (2002) (156)
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. (1995) (154)
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. (1999) (149)
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. (2009) (149)
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors (2006) (139)
Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib (2005) (137)
AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor (2007) (136)
In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. (1988) (133)
Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS) (2011) (128)
Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). (2009) (124)
Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma (2011) (120)
Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. (2005) (118)
Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation (2012) (118)
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells (2004) (116)
Emerging ethnic differences in lung cancer therapy (2008) (115)
Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474 (2004) (113)
Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer (2008) (112)
Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. (1992) (107)
Effects of β- and γ-carboline derivatives on DNA topoisomerase activities (1996) (104)
The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. (1990) (102)
Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells (2004) (101)
[Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment]. (2003) (100)
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. (2003) (99)
Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients (2003) (95)
Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. (2015) (94)
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. (2008) (94)
Serum levels of cytokines in patients with untreated primary lung cancer. (1996) (93)
Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin (2005) (93)
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway (2007) (91)
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. (2009) (91)
Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. (2000) (91)
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. (2014) (90)
Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. (1992) (90)
Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa® (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line in vitro and in vivo (2002) (89)
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer (2008) (88)
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. (2005) (87)
Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line (1990) (86)
Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel (2011) (86)
LEVELS OF GLUTATHIONES TRANSFERASE π mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN (1988) (86)
Osteopontin induces angiogenesis of murine neuroblastoma cells in mice (2002) (85)
Small cell lung cancer. (1997) (84)
Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions (1995) (83)
Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. (1999) (83)
A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. (2004) (83)
Indirect‐response model for the time course of leukopenia with anticancer drugs (1998) (82)
Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? (2004) (82)
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan (2003) (81)
Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. (1991) (81)
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. (2005) (81)
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma (2010) (79)
Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. (1989) (79)
A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38 (1995) (79)
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study (2008) (78)
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. (1998) (77)
Haplotype structures of the UGT1A gene complex in a Japanese population (2006) (76)
Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion (1993) (76)
Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. (1995) (73)
Characterization of a Taxol‐resistant Human Small‐cell Lung Cancer Cell Line (1994) (73)
A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811) (2009) (72)
A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511) (2000) (72)
Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). (2005) (72)
Intradural parenchymal involvement in the spinal subarachnoid space associated with primary lung cancer (1993) (69)
In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay (2004) (69)
Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities (1995) (69)
Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. (2014) (69)
Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. (1994) (69)
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). (2009) (68)
Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. (1993) (66)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). (2009) (66)
Increased cytotoxic effects of photodynamic therapy in IL‐6 gene transfected cells via enhanced apoptosis (2001) (64)
In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. (1997) (63)
Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. (1996) (63)
Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. (2006) (63)
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models (2004) (63)
Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. (1991) (63)
Antitumor activity of daphnane‐type diterpene gnidimacrin isolated from Stellera chamaejasme L (1996) (63)
Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy (1986) (60)
Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. (1992) (60)
In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. (2001) (60)
Paclitaxel-Induced Cell-Mediated Hypersensitivity Pneumonitis (1998) (60)
Establishment and characterization of cisplatin‐resistant sublines of human lung cancer cell lines (1988) (60)
An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. (1998) (59)
A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606) (2010) (59)
Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. (2003) (58)
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. (1996) (57)
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients (2010) (57)
Genetic variations and haplotypes of UGT1A4 in a Japanese population. (2005) (56)
In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. (1989) (56)
Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer (2007) (56)
FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION (2005) (55)
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients (2009) (55)
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences (2007) (54)
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. (2010) (53)
Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients 1 (2003) (53)
Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. (1995) (53)
Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition (2010) (52)
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. (1997) (52)
Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. (2001) (52)
Antitumor activity of TZT‐1027 (Soblidotin) against vascular endothelial growth factor‐secreting human lung cancer in vivo (2003) (51)
Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age (2000) (50)
Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer. (1985) (50)
Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. (2007) (50)
Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells (2001) (50)
Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients (2010) (50)
Enhanced interaction between tubulin and microtubule‐associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel (1995) (50)
Prognostic factors and prognostic staging system for small cell lung cancer. (1997) (49)
Drug resistance in lung cancer. (1999) (49)
Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. (1997) (49)
1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. (1996) (49)
Japan Clinical Oncology Group (JCOG). (1998) (49)
Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. (2009) (48)
Dimerization and the signal transduction pathway of a smallin‐frame deletion in the epidermal growth factor receptor (2006) (48)
The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). (2004) (48)
The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP) (1993) (48)
FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2) (2005) (47)
Functional analysis of four naturally occurring variants of human constitutive androstane receptor. (2005) (47)
Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). (2006) (46)
Combination effect of vaccination with IL2 and IL4 cdna transfected cells on the induction of a therapeutic immune response against lewis lung carcinoma cells (1993) (46)
Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. (2006) (45)
Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer (2008) (45)
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. (2008) (44)
Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer (2006) (44)
Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay (2004) (43)
Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy (2008) (43)
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). (2014) (43)
Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. (2006) (42)
Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells. (1994) (42)
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. (2013) (42)
Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. (1995) (42)
Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L. (2011) (42)
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer (2001) (41)
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. (2010) (41)
Three novel single nucleotide polymorphisms in UGT1A9. (2003) (40)
Identification of a predictive biomarker for hematologic toxicities of gemcitabine. (2009) (40)
cDNA cloning of a short type of multidrug resistance protein homologue, SMRP, from a human lung cancer cell line. (1997) (40)
Phase II study of UFT in patients with advanced non-small cell lung cancer. (1986) (40)
Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line (1991) (39)
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. (2017) (39)
Pilot Study of Concurrent Etoposide and Cisplatin Plus Accelerated Hyperfractionated Thoracic Radiotherapy Followed by Irinotecan and Cisplatin for Limited-Stage Small Cell Lung Cancer: Japan Clinical Oncology Group 9903 (2005) (38)
KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. (2013) (38)
Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. (1996) (38)
Concurrent Chemoradiotherapy with Cisplatin and Vinorelbine for Stage III Non-small Cell Lung Cancer (2008) (37)
Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment* (2010) (37)
Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer. (1995) (37)
Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo (2010) (37)
Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11 (1995) (37)
Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. (2000) (37)
Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. (2003) (37)
Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. (2001) (36)
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer (2015) (36)
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. (2010) (36)
Platinum-based chemotherapy with or without thoracic radiation therapy in patients with unresectable thymic carcinoma. (2000) (36)
Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non‐small cell lung cancer (2004) (35)
Three novel single nucleotide polymorphisms in UGT1A10. (2002) (35)
Genetic polymorphisms of UGT1A6 in a Japanese population. (2005) (35)
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. (1997) (35)
Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). (2006) (35)
Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. (1999) (35)
Long-term human hematopoiesis in SCID-hu mice bearing transplanted fragments of adult bone and bone marrow cells. (1995) (34)
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. (2009) (34)
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer (2009) (34)
P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors (2003) (33)
Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib (2005) (33)
Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. (1986) (33)
Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay (2004) (32)
Mechanism of action of aragusterol a (YTA0040), a potent anti‐tumor marine steroid targeting the G1 phase of the cell cycle (2000) (32)
Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells (1999) (32)
Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer (2006) (32)
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer 1 (2010) (32)
Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study (2009) (32)
Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy. (1989) (32)
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer (2004) (31)
A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy (2004) (31)
Evaluation of synergism by a novel three‐dimensional model for the combined action of cisplatin and etoposide on the growth of a human small‐cell lung‐cancer cell line, SBC‐3 (1997) (31)
Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. (2007) (31)
Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. (1999) (31)
Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. (2007) (31)
Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. (2009) (31)
Measurement and verification of positron emitter nuclei generated at each treatment site by target nuclear fragment reactions in proton therapy. (2010) (31)
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. (2012) (30)
Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay. (1985) (30)
Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. (2002) (30)
Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes. (1993) (30)
Preferential Binding of E7010 to Murine β3‐Tubulin and Decreased β3‐Tubulin in E7010‐resistant Cell Lines (1998) (30)
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). (2012) (30)
Identification ofcis-Acting DNA Elements of the Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene (1997) (30)
Present Status and Problems on Molecular Targeted Therapy of Cancer (2012) (30)
A Novel Antitumor Antibiotic, KW‐2189 Is Activated by Carboxyl Esterase and Induces DNA Strand Breaks in Human Small Cell Lung Cancer Cells (1994) (29)
Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation (2011) (29)
Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells (2004) (29)
Antitumor activity of a new platinum compound (glycolate-o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. (1988) (28)
Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese (2009) (28)
Chemotherapy-induced anemia in patients with primary lung cancer. (1992) (28)
Postoperative adjuvant treatments for non-small cell lung cancers: a consensus report (1991) (28)
Haplotypes and a Novel Defective Allele of CES2 Found in a Japanese Population (2007) (28)
Severe Interstitial Lung Disease Associated with Amrubicin Treatment (2010) (28)
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). (2003) (28)
Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. (2004) (27)
Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments] (1998) (27)
Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo (1997) (27)
A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. (1991) (27)
Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer (1990) (27)
Strategy for the development of novel anticancer drugs (2003) (27)
Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. (2008) (27)
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population (2007) (27)
Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results. (1995) (26)
Molecular determinants of UCN‐01‐induced growth inhibition in human lung cancer cells (2000) (26)
Cancer chemotherapy in the elderly. (1998) (26)
Detailed structural analysis on both human MRP5 and mouse mrp5 transcripts. (2000) (26)
Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines. (1997) (26)
A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605) (2009) (26)
Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients. (1994) (25)
A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer. (2014) (25)
Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. (2016) (25)
Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. (2002) (25)
FUNCTIONAL ANALYSIS OF SIX HUMAN ARYL HYDROCARBON RECEPTOR VARIANTS IN A JAPANESE POPULATION (2005) (25)
Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A) (2003) (25)
Preclinical and Clinical Trials of Topoisomerase Inhibitors (2000) (25)
The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function (2004) (25)
Mechanism of antitumor action of PKC activator, gnidimacrin (1998) (24)
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. (2006) (24)
Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion. (1998) (24)
Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. (2010) (24)
A Multi-Institution Phase I/II Trial of Triweekly Regimen with S-1 Plus Cisplatin in Patients with Advanced Non-small Cell Lung Cancer (2010) (24)
A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer (2006) (24)
Genetic Variations and Haplotype Structures of the ABCB1 Gene in a Japanese Population: An Expanded Haplotype Block Covering the Distal Promoter Region, and Associated Ethnic Differences (2006) (24)
Effects of beta- and gamma-carboline derivatives of DNA topoisomerase activities. (1996) (24)
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients (2008) (24)
Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung. (1982) (24)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). (2009) (23)
Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion (1994) (23)
Clinical Trials of Irinotecan Hydrochloride (CPT, Campto Injection, Topotecin Injection) in Japan a (1996) (23)
Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. (1989) (23)
Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells. (1993) (23)
Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. (2007) (23)
The value of two‐dimensional echocardiography in detecting malignant tumors in the heart (1986) (23)
A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin (1994) (22)
Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†. (2015) (22)
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. (1986) (22)
Genetic polymorphisms and haplotypes of por, encoding cytochrome p450 oxidoreductase, in a Japanese population. (2011) (22)
Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action. (1994) (22)
Genistein, a Tyrosine Kinase Inhibitor, Decreased the Affinity of p56lck to β-Chain of Interleukin-2 Receptor in Human Natural Killer (NK)-Rich Cells and Decreased NK-Mediated Cytotoxicity (1994) (22)
Interleukin-2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors. (1997) (22)
Biological, pathological and clinical features of small cell lung cancer. (1986) (22)
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. (2006) (22)
Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II). (1992) (22)
Characterisation of a vindesine-resistant human small-cell lung cancer cell line. (1993) (22)
Progress in treatment of small-cell lung cancer: role of CPT-11 (2003) (22)
In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. (1995) (22)
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials (2009) (22)
Characterization of an etoposide-resistant human small-cell lung cancer cell line (2008) (22)
p16INK4 Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors (1997) (21)
Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin. (1990) (21)
Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray. (2001) (21)
Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray. (2002) (21)
Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). (2003) (21)
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. (2006) (21)
Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D) (1990) (21)
Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials (2004) (21)
Evidence‐based clinical practice guidelines for bladder cancer (Summary – JUA 2009 Edition) (2010) (21)
Glutathione homeostasis in human hepatic cells: overexpression of gamma-glutamylcysteine synthetase gene in cell lines resistant to buthionine sulfoximine, an inhibitor of glutathione synthesis. (1998) (21)
Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells (1999) (20)
Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells (2002) (20)
Disparities in cancer care: a worldwide perspective and roadmap for change. (2006) (20)
Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. (1989) (20)
Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients. (2008) (20)
Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population. (2005) (20)
Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. (2000) (20)
Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124 (2007) (20)
Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer. (1998) (19)
Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro. (1995) (19)
The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology (2012) (19)
Prediction of hematologic toxicity of carboplatin by creatinine clearance rate. (1987) (19)
Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL‐2 gene‐modified Lewis lung carcinoma cells (1997) (19)
Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population. (2003) (19)
Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GMl antibody or anticancer agents (2005) (19)
Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. (2001) (19)
Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: Individual patient data from Japanese randomized, placebo‐controlled trials (2013) (19)
Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. (2010) (19)
Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin (2002) (19)
Lung cancer working group report. (2010) (19)
Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702 (2005) (19)
A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis (1996) (19)
Adenovirus‐mediated p16 gene transfer prevents drug‐induced cell death through G1 arrest in human glioma cells (1998) (19)
Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207 (2007) (19)
CIS‐diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung‐cancer cells (1993) (18)
Effect of a chimeric anti‐ganglioside GM2 antibody on ganglioside GM2‐expressing human solid tumors In vivo (1999) (18)
Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma (2016) (18)
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507 (2003) (18)
A Randomized Prospective Study of Imipenem‐Cilastatin With or Without Amikacin as an Empirical Antibiotic Treatment for Febrile Neutropenic Patients (1994) (18)
Establishment of a human leukemia subline resistant to the growth‐inhibitory effect of 12‐o‐tetradecanoylphorbol 13‐acetate (TPA) and showing non‐P‐glycoprotein‐mediated multi‐drug resistance (1991) (18)
Progress in cancer chemotherapy with special stress on molecular-targeted therapy. (2010) (18)
Phase II study of carboplatin in small cell lung cancer. (1988) (18)
A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro (2005) (18)
Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). (2008) (17)
Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. (2001) (17)
Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. (2008) (17)
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. (2009) (17)
Cytogenetic effects of etoposide (VP-16) on human lymphocytes; with special reference to the relation between sister chromatid exchange and chromatid breakage. (1986) (17)
Rapid Polymerase Chain Reaction Assay to Detect Variation in the Extent of Gene‐specific Damage between Cisplatin‐ or VP‐16‐resistant and Sensitive Lung Cancer Cell Lines (1994) (17)
Dose-intensive chemotherapy in extensive-stage small-cell lung cancer (1997) (17)
Re-challenge chemotherapy for relapsed non-small-cell lung cancer. (2010) (17)
In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. (2006) (17)
CPT‐11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer (1994) (17)
A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients (2001) (17)
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience. (1998) (17)
Recent trends in the treatment of advanced lung cancer (2006) (17)
AZD 2171 Shows Potent AntitumorActivityAgainst Gastric Cancer OverExpressing Fibroblast Growth Factor Receptor 2 / Keratinocyte Growth Factor Receptor (2007) (17)
Ouabain‐resistant non‐small‐cell lung‐cancer CELL LINE SHOWS COLLATERAL SENSITIVITY TO cis‐diamminedichloroplatinum(II) (CDDP) (1994) (17)
Clonogenic cell assay for carcinoma of the lung. (1984) (17)
Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion (2008) (16)
Correlation between drug sensitivity determined by clonogenic cell assay and clinical effect of chemotherapy in patients with primary lung cancer. (1984) (16)
Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials. (2004) (16)
Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f (1998) (16)
Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level (1988) (16)
A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204) (2008) (16)
Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status. (1996) (16)
Differential gene expression profiles and identification of the genes relevant to clinicopathologic factors in colorectal cancer selected by cDNA array method in combination with principal component analysis. (2003) (16)
Pharmacokinetic Study of Mitomycin C with Emphasis on the Influence of Aging (1992) (16)
Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non‐small cell lung cancer patients (2006) (16)
Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells. (1999) (16)
Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review. (2007) (16)
Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan) (2004) (16)
Novel combination chemotherapy in the treatment of non-small cell lung cancer (2000) (16)
Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study. (2006) (16)
A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. (2009) (16)
In vitro thermo- and thermochemo-sensitivity of retinoblastoma cells from surgical specimens (2002) (15)
Enhanced antitumor activities of TZT-1027 against TNF-α or IL-6 secreting Lewis lung carcinoma in vivo (2001) (15)
In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin (2004) (15)
Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung (2004) (15)
A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer. (1991) (15)
A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38 (1995) (15)
Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma (2004) (15)
Retrospective Analysis of Safety and Efficacy of Low-Dose Docetaxel 60 mg/m2 in Advanced Non–Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy (2003) (15)
Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. (2006) (15)
Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer (2004) (15)
Developments for a growing Japanese patient population: facilitating new technologies for future health care. (2011) (15)
Concurrent versus sequential radiotherapy for small cell lung cancer. (2001) (15)
Increased phosphorylation of nuclear phosphoproteins in human lung‐cancer cells resistant to cis‐diamminedichloroplatinum(II) (1992) (15)
Recurrence of thymoma with appearance of myasthenia gravis 18 years after surgery: a case report. (1985) (14)
Distal promoter regions are responsible for differential regulation of human orosomucoid-1 and -2 gene expression and acute phase responses. (2014) (14)
Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma. (1986) (14)
Overcoming multi‐drug resistance using an intracellular anti‐MDR1 sFv (2001) (14)
Problems in the development of target-based drugs (2000) (14)
A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies (2009) (14)
Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. (2009) (14)
Proximal 5'-flanking sequence of the human gamma-glutamylcysteine synthetase heavy subunit gene is involved in cisplatin-induced transcriptional up-regulation in a lung cancer cell line SBC-3. (1997) (14)
Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL-2) against lung cancer cell lines by human tumor clonogenic assay (HTCA). (1986) (14)
Synergistic inhibition of the growth of adenocarcinoma 755 by the combination of interleukin-2 and interferon-.BETA.. (1986) (13)
Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104). (2004) (13)
Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group. (1994) (13)
Reversal of adriamycin resistance with chimeric anti‐ganglioside GM2 antibody (1996) (13)
Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS). (2006) (13)
Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104) (2004) (13)
Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. (2008) (13)
Antitumor action of the PKC activator gnidimacrin through cdk2 inhibition (2001) (13)
Translational study in cancer research. (2002) (13)
Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line (2005) (12)
Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy. (2008) (12)
Small-cell lung cancer: current therapy and novel agents. (2005) (12)
Efficient Sampling Strategies for Forecasting Pharmacokinetic Parameters of Irinotecan (CPT‐11): Implication for Area Under the Concentration‐Time Curve Monitoring (1995) (12)
Targeted therapies: Tyrosine-kinase inhibitors—new standard for NSCLC therapy (2010) (12)
Phase I study of weekly docetaxel (DTX) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC) (2000) (12)
Experimental and clinical effect of ACNU in Japan, with emphasis on small-cell carcinoma of the lung (2004) (12)
Chemotherapy: the more the better? Overview (1997) (12)
Gene Expression Profiling of Exposure to TZT-1027, a Novel Microtubule-Interfering Agent, in Non-Small Cell Lung Cancer PC-14 Cells and Astrocytes (2004) (12)
Cytogenetic effects of multiagent chemotherapy on the peripheral lymphocytes of patients with small cell lung cancer. (1986) (12)
In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant (2005) (12)
In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity. (1987) (12)
What are the reasons for negative phase III trials of molecular‐target‐based drugs? (2004) (12)
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer (2009) (12)
In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines (1994) (12)
[Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies]. (1998) (12)
Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. (2006) (12)
Translational and clinical studies of target-based cancer therapy (2003) (11)
9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS (2011) (11)
Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan (2010) (11)
Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients. (2011) (11)
Ectopic p16ink4 expression enhances CPT‐11‐induced apoptosis through increased delay in S‐phase progression in human non‐small‐cell‐lung‐cancer cells (2000) (11)
Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid (2005) (11)
Effect of ACNU on primary lung cancer, mesothelioma, and metastatic pulmonary tumors. (1978) (11)
Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population. (2009) (11)
O-269 A phase II trial of pre-operative chemoradiotherapy followed by surgery in Pancoast tumors: initial report of Japan Clinical Oncology Group trial (JCOG 9806) (2003) (11)
Colony Inhibitory Effect of Recombinant Human Tumor Necrosis Factor (rH-TNF) and/or Recombinant Human Interferon (rH-IFN)-α -β and -γ on Human Lung Cancer Cell Lines (1987) (11)
In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. (2003) (11)
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). (2012) (11)
The final results of a randomized phase III trial comparing irinotecan (CPT-11) and cisplatin (CDDP) with vindesine (VDS) and CDDP in advanced non-small cell lung cancer (NSCLC) (2000) (11)
Phase II study of cis-diamminedichloroplatinum in patients with non-small cell lung cancer. (1985) (10)
Apoptosis induced by etoposide in small-cell lung cancer cell lines (2004) (10)
Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl. (2007) (10)
In vivo and in vitro effects of Nocardia rubra cell wall skeleton on natural killer activity in mice. (1983) (10)
Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients (2010) (10)
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer. (2002) (10)
Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancer. (2003) (10)
Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice. (1978) (10)
Circumvention of glutathione‐mediated mitomycin C resistance by a novel mitomycin C analogue, KW‐2149 (1997) (10)
The frequency and management of infectious episodes and sepsis in small cell lung cancer patients receiving intensive chemotherapy with granulocyte-colony stimulating factor. (1991) (10)
Sister chromatid exchanges induced in human lymphocytes by cis-diamminedichloroplatinum (II). (1984) (10)
Long-term survival in patients with small cell lung cancer. (1986) (10)
Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP (1992) (10)
Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. (2000) (10)
P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non–small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies (2007) (10)
Mechanisms of Action of Cancer Chemotherapeutic Agents: Topoisomerase Inhibitors (2005) (10)
A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies (2005) (10)
Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene (1997) (10)
Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial. (1986) (10)
In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model (1999) (10)
Slug Increases Sensitivity To Tubulin Binding Agents Via The Downregulation Of Beta III And IVa-Tubulin In Lung Cancer Cells (2012) (10)
Participation of poly(ADP-robose) polymerase in the drug sensitivity in human lung cancer cell lines (2005) (10)
The Incidence of Cardiac Metastasis in Primary Lung Cancer and the Management of Malignant Pericardial Effusion (1982) (9)
A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer. (2001) (9)
Report of the Seventh International Symposium of the Foundation for Promotion of Cancer Research: fundamental and clinical research in lung cancer. (1994) (9)
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer (2008) (9)
Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562/TPA cells. (2003) (9)
Oxford Textbook of Oncology (2016) (9)
Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. (2016) (9)
Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs (1989) (9)
Combined modality therapy for small cell lung cancer. (1992) (9)
A phase II trial of low-dose docetaxel (DCT) 60 mg/m2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC) (2000) (9)
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. (2011) (9)
Characterization of an etoposide-resistant human ovarian cancer cell line (2004) (9)
The Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC): A subgroup analysis in elderly patients (pts) (2006) (9)
Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung. (1983) (9)
Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population. (2004) (9)
Primary lung cancer in an 18-year-old boy: case report. (1990) (9)
Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation (2005) (9)
In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells (1997) (8)
Translational studies for target-based drugs (2005) (8)
The Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC): A subgroup analysis in elderly patients (pts). (2006) (8)
Geographic variation in the second-line treatment of non-small cell lung cancer. (2006) (8)
A case report of a three-year survivor with advanced non-small cell lung cancer producing alpha-fetoprotein. (1986) (8)
Cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) in advanced (stage IIIB and stage IV) non-small cell lung cancer (NSCLC). A multicenter phase III study (1999) (8)
Cytogenetic effect of carboplatin on human lymphocytes (2004) (8)
Collateral sensitivity of cisplatin-resistant human lung cancer cell lines to thymidylate synthase inhibitors (1990) (7)
Differential macrophage-mediated cytotoxicity to P388 leukemia cells and its drug-resistant cells examined by a new MTT assay. (1992) (7)
Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601). (2001) (7)
[A summary report of response evaluation criteria in solid tumors (RECIST criteria)]. (2000) (7)
Detection of Proteins that Recognize Platinum‐modified DNA Using Gel Mobility Shift Assay (1990) (7)
Lack of correlation between interferon levels induced by polyribonucleotides and their antimetastatic effect. (1990) (7)
Phase II study of vindesine in patients with non-small cell lung cancer. (1985) (7)
Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect (2014) (7)
Phase II study of oral administration of 5'-deoxy-5-fluorouridine (5'-DFUR) for solid tumors. (1984) (7)
Culture of retinoblastoma cells from clinical specimens: growth-promoting effect of 2-Mercaptoethanol (2005) (7)
Identification of cis-acting DNA elements of the human gamma-glutamylcysteine synthetase heavy subunit gene. (1997) (7)
Cytoskeletons and antimitotic agents developed in Japan. (1999) (7)
Basic Design Considerations for Clinical Trials in Oncology (1992) (7)
Results of recent Japanese clinical trials in lung cancer. (2002) (7)
A randomized phase II study of 500 mg/m2 and 1,000 mg/m2 of pemetrexed in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had prior chemotherapy (2007) (7)
The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin. (1998) (7)
[Globalization of clinical trials]. (2003) (7)
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (final report). (2004) (7)
New strategies for cancer therapy in the 21st century (2001) (7)
The antitumor activity of radiation therapy is reduced in patients with non-small-cell carcinoma of the lung refractory to chemotherapy. (1992) (7)
A new MTT assay for examining the cytotoxicity of activated macrophages towards the non-adherent P388 leukaemia cell line. (1992) (7)
Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant (2012) (7)
Antitumor effect of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide on human pulmonary adenocarcinoma cell lines in tumor clonogenic assay. (1986) (7)
A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer. (2001) (7)
[Microtubules and antineoplastic drugs]. (1994) (7)
Advances in Personalized Therapy for Lung Cancer (2011) (7)
Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity (1989) (7)
A phase II study of induction chemotherapy (Ind CT) with CPT-11 and cisplatin followed by thoracic radiation (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small-cell lung cancer (NSCLC): A Japan Clinical Oncology (JCOG) 9706 Trial (2000) (7)
Acquired factor VIII inhibitor in a patient with adenocarcinoma of the lung. (1992) (7)
Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402. (2010) (6)
A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509. (2012) (6)
Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma (2011) (6)
Malignant germ cell tumor of the mediastinum: A multimodality therapeutic approach (1994) (6)
Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line. (1992) (6)
Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer. (2002) (6)
In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice (2004) (6)
D256N, found in Japanese cancer patients (2003) (6)
Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent. (1986) (6)
Establishment of a human small‐cell lung‐cancer subline resistant to okadaic acid (1994) (6)
Effect of combination treatment with mitomycin-c and lysosome labilizers on nodular pulmonary metastases. (1974) (6)
A randomized phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): Preliminary results. (2006) (6)
Effects of BCG and 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) on the cytostatic activity of macrophages in normal and tumour-bearing rats. (1980) (6)
Hypersensitivity of NIH3T3 cells transformed by H‐RAS gene to DNA‐topoisomerase‐I inhibitors (1996) (6)
Problems involved in the clinical trials for non-small cell lung carcinoma. (2012) (6)
Randomized phase II study of cisplatin , irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer ( JCOG 9902-DI ) (2003) (6)
Human tumor clonogenic assay for carcinoma of the lung. II. Factors that influence colony formation in soft agar. (1987) (6)
Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients. (2011) (6)
Phase II study of mitoxantrone in patients with non-small cell lung cancer. (1986) (6)
Effects of BCG and cyclophosphamide on the spontaneous and antibody-dependent cell-mediated cytotoxicity of peritoneal and spleen lymphocytes of ACI/N rats. (1982) (6)
A Computational Model for Quantitative Analysis of Cell Cycle Arrest and Its Contribution to Overall Growth Inhibition by Anticancer Agents (2000) (6)
Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. (2008) (6)
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? (2008) (6)
hnRNP L enhances sensitivity of the cells to KW‐2189 (2004) (6)
Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial. (1997) (6)
Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer : Long-term follow-up results (2005) (6)
A case report of synchronous small cell lung cancer and gastric cancer successfully treated with carboplatin. (1986) (5)
ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study. (2002) (5)
[Clinical trial of IL-12 for cancer patients]. (1998) (5)
[Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor]. (1983) (5)
Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy. (2010) (5)
Genome-wide association scan detected candidate polymorphisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX). (2016) (5)
Suppression of natural killer activity in patients treated with cisplatin and methylprednisolone (2005) (5)
Recent development of molecular-targeted drugs in lung cancer. (2010) (5)
Effect of 1(4-Amino-2-methyl-5-pyrimidinyI), methyl-3-(2-chloroethyl)-3-nitrosourea Hydrochloride (ACNU) on Sato Lung Carcinoma (SLC) (1979) (5)
A bioassay of cisplatin by human tumor clonogenic assay. (1986) (5)
Decreased Expression of α2,8 Sialyltransferase and Increased Expression of β1,4 N-Acetylgalactosaminyltransferase in Gastrointestinal Cancers (2002) (5)
Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience. (2004) (5)
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines (2004) (5)
Human Lung Cancer Cell Lines (1995) (5)
Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay (1995) (5)
[Platinum compounds in cancer therapy--past, present, and future]. (2001) (5)
Randomized study of vinorelbine (VRB) or vindesine (VDS) with cisplatin (P) and mitomycin (M) as induction chemotherapy in stage IIIB or IV non-small cell lung cancer (NSCLC) — Final results (2000) (5)
A phase I study of the chimeric monoclonal anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a single agent in subjects from Japan with advanced solid tumors: Safety, pharmacokinetics (PK) (2005) (5)
Combined effect of BCG and coenzyme Q10 on ATP-ase activity and coenzyme Q content in spleen lymphocytes of tumor-bearing rats. (1979) (5)
Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC). (2006) (5)
Dose intensity of irinotecan (CPT) combined with weekly cisplatin (DDP) and etoposide (ETOP) in patients (pts) with metastatic lung cancer (LC): Phase I/II study JCOG 9507 (2000) (5)
Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines. (1987) (5)
FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP 2 C 8 VARIANTS , G 171 S , R 186 X , R 186 G , K 247 R , AND K 383 N , FOUND IN A JAPANESE POPULATION (2005) (5)
Docetaxel (D) consolidation therapy following cisplatin (P), vinorelbine (V) and concurrent thoracic radiotherapy (TRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC) (2005) (5)
Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306. (2002) (5)
Evaluation of the effects of chemotherapy in lung cancer by thoracic computed tomography (1988) (5)
O-72 A pilot study of cisplatin and etoposide plus concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) followed by three cycles of irinotecan and cisplatin for the treatment of limited-stage small-cell lung cancer (SCLC): JCOG 9903-DI (2003) (5)
Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final "common arm": Comparative outcomes analysis of JCOG 9511 and SWOG 0124. (2016) (5)
6560 POSTER Prognostic factors affecting survival on pretreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) – Subgroup analysis in a randomized Ph II study of pemetrexed 500 mg/m2 and 1000 mg/m2 (2007) (5)
In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay. (1986) (5)
Abstract 1639: The novel c-MET inhibitor, ARQ 197, shows additive growrh-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via ubiquitin/proteasome pathway (2010) (5)
Phase II study of carboplatin in non-small cell lung cancer. (1989) (5)
A case report of pulmonary adenocarcinoma responding to (glycolato-0,0') diammineplatinum (II), a new platinum complex. (1987) (4)
Effect of Propionibacterium acnes or BCG on enzyme activities in spleen lymphocytes of Donryu strain rats. (1978) (4)
The use of human tumor clonogenic assay in predicting combination effect of cisplatin plus vindesine in carcinoma of the lung. (1985) (4)
Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. (2003) (4)
Synergistic effect of recombinant interleukin-2 on the inhibition of growth of adenocarcinoma 755 by mitomycin. (1987) (4)
9008 Clinical outcomes of bevacizumab in combination with paclitaxel/carboplatin compared with paclitaxel/carboplatin alone in previously untreated Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC) (2009) (4)
Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group. (1998) (4)
[Recent status of the diagnosis and treatment of bone metastasis in patients with advanced lung cancer]. (1987) (4)
Phase II of ACNU for non-small cell lung cancer. (1985) (4)
In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2) (2004) (4)
In vitro chemosensitivity patterns of carcinoma of the lung in human tumor clonogenic assay. (1986) (4)
Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population. (2007) (4)
[Effect of Nocardia rubra cell wall skeleton against pleuritis carcinomatosa in adenocarcinoma of the lung]. (1983) (4)
Large cell carcinoma of the lung secreting human chorionic gonadotropin which responded to combination chemotherapy: case report. (1990) (4)
Pulmonary toxicity induced by pepleomycin 3-[(S)-1'-phenylethylamino] propylamino-bleomycin. (1983) (4)
Updated results of a phase III trial comparing standard thoracic radiotherapy (RT) with or without concurrent daily low-dose carboplatin in elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC): JCOG0301. (2012) (4)
Effect of taxol on vinblastine sulfate-induced crystallization of tubulin. (1993) (4)
Adenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells. (1998) (4)
Phase I and pharmacokinetic (PK) study of Nedaplatin (254-S) in elderly patients with advanced non-small cell lung cancer (NSCLC) (2000) (4)
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. (2009) (4)
Comparative study of the antitumor effect of two types of murine recombinant interferons, (beta) and (gamma), against B16-F10 melanoma. (1988) (4)
Small cell lund cancer (1997) (4)
Chemoradiation therapy in patients (pts) with small cell lung cancer (SCLC) with pericardial effusion but no distant metastasis. (2009) (4)
A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer. (2001) (4)
Guidelines for Analysis and Reporting of Clinical Trials in Oncology (1993) (4)
Cooperative group research endeavors in small-cell lung cancer: current and future directions. (2009) (3)
PHYTOHEMAGGLUTININ SKIN TEST (1975) (3)
Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519 (2001) (3)
[Clinical trial of KRN 8601 in patients with neutropenia induced by chemotherapy for lung cancer]. (1990) (3)
Topoisomerase i targeting agents in small-cell lung cancer (2001) (3)
A CASE OF THYMOMA WITH EXTRATHORACIC METASTASES (1975) (3)
Effect of cytidine deaminase (CDA)-related biomarkers on overall survival in patients with advanced pancreatic cancer receiving gemcitabine (GEM) monotherapy. (2011) (3)
Comparative studies of pulse and continuous exposure in human tumor clonogenic assay. (1987) (3)
The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines (2004) (3)
Induction of cytochrome P450 (CYP3A4) by gefitinib in non-small cell lung cancer (NSCLC) patients (2005) (3)
[A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine]. (1987) (3)
Histologic types of lung carcinoma and related family history of anatomic sites and histologic types of cancers (1999) (3)
An integrated analysis of comprehensive geriatric assessment (CGA) in elderly patients with non-small cell lung cancer (NSCLC) (JCOG1115-A). (2012) (3)
Phorbol ester and okadaic acid-resistant cells: the crossroads of signal transduction and drug resistance. (1995) (3)
Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study (2020) (3)
広範囲疾患小細胞肺癌(ED‐SCLC)の高齢又は予後不良患者におけるカルボプラチン(Cb)又はエトポシド(E)とシスプラチン(P)との多剤併用無作為第III相試験:日本臨床腫瘍学グループ治験報告(JCOG9702) (2005) (3)
Once weekly epoetin beta to increase hemoglobin and improve quality of life in anemic cancer patients receiving chemotherapy: A randomized, double-blind, dose-finding study (2004) (3)
Differences of host immune response and of sensitivity to chemotherapeutic agents between two clones of rat fibrosarcoma with different metastatic potential. (1986) (3)
Preface for JCOG review series. (2011) (3)
[Post launch studies]. (2002) (3)
Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. (2007) (3)
Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity. (2000) (3)
Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors. (1985) (3)
[Phase II study of vindesine in patients with carcinoma of the lung and metastatic pulmonary tumor]. (1982) (3)
Growth-stimulating pathways in lung cancer: implications for targets of therapy. (2001) (3)
In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance (2005) (3)
[Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group]. (1996) (3)
Clinical significance of chemotherapy for small cell lung cancer (SCLC) with ECOG performance status (PS) 3-4 (2008) (3)
P2-274: Clinical benefits of pemetrexed 500 mg/m2 and 1000 mg/m2 in a randomized phase II study for pretreated patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) (2007) (3)
Cellular balance of glutathione levels through the expression of gamma-glutamylcysteine synthetase and glutathione thiol transferase genes in human hepatic cells resistant to a glutathione poison. (1999) (3)
Establishment of a human retinoblastoma cell line: NCC-RbC-39 (1991) (3)
Irinotecan Combined with Radiation Therapy for Patients with Stage III Non-Small-Cell Lung Cancer: Current Trials. (2002) (3)
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408. (2000) (3)
Chemosensitivity test for human small cell lung cancer cell lines in vitro. (1986) (3)
Advances in the treatment of non-small cell lung cancer. (2008) (3)
[Molecular target therapy in cancer]. (2010) (2)
[Apoptosis and chemosensitivity]. (1997) (2)
O-219 Preliminary results of four arm cooperative study (FACS) for Advanced Non-Small Cell Lung Cancer (NSCLC) in Japan (2003) (2)
The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer. (1994) (2)
[Induction of tumor immunity by cytokine cDNA transfected Lewis lung carcinoma]. (1992) (2)
Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer. (1993) (2)
Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6 (2001) (2)
未治療の非小細胞肺癌患者に対するゲフィチニブとカルボプラチン・パクリタキセルの第III相国際共同試験（IPASS）の全生存期間最終解析 (2012) (2)
[Signal transduction inhibitor]. (2001) (2)
Effect of 1(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) on Sato lung carcinoma (SLC). Preliminary result of immunochemotherapy for SLC by combination of ACNU and Propionibacterium acnes. (1979) (2)
Dose intensive chemotherapy (Cx) in advanced thymoma: Initial report of Japan Clinical Oncology Group trials (JCOG 9605 and 9606). (2006) (2)
[The relation between myelotoxicity and performance status or aging in chemotherapy of non-small cell lung cancer]. (1991) (2)
The impact of an independent response evaluation committee (REC) using RECIST guidelines in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan. (2004) (2)
CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver (2001) (2)
A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone (D) in clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Initial report of Japan Clinical Oncology Group trial (JCOG 0204) (2005) (2)
Enzyme activities in spleen lymphocytes of tumor-bearing rats, and effect of Propionibacterium acnes, BCG, and toxohormone on the enzyme activities in spleen lymphocytes of rats. (1981) (2)
Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806). (2010) (2)
The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro. (1988) (2)
Reply to ‘Malignant pericardial effusion: sclerotherapy or local chemotherapy?’ (2009) (2)
Changes of enzyme activities in spleen lymphocytes from tumor-bearing rats. (1975) (2)
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines. (2009) (2)
Comparative study of the antitumor effect of two types of murine recombinant interferons, (β) and (γ), against B16-F10 melanoma (2004) (2)
DIFFERENTIATION OF Ca 2+ SIGNALLING BETWEEN ADRIAMYCIN-SENSITIVE AND RESISTANT CELL LINES OF HUMAN LUNG CANCER, SBC-3 (1996) (2)
[Anticancer agents and apoptosis]. (1994) (2)
[Effect of cisplatin on cell cycle regulators]. (1994) (2)
Activation-Induced Apoptosis of Peripheral Lymphocytes Treated with 7-Hydroxystaurosporine, UCN-01 (1999) (2)
Roentgenographically occult small-cell lung cancer: case report and review of the literature. (1996) (2)
[Genetic testing for effective Herceptin therapy]. (2002) (2)
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes (1996) (2)
Molecularly Targeted Therapy for Lung Cancer: Recent Topics (2008) (2)
Novel Water-Soluble Derivatives of Docosahexaenoic Acid Increase Diacylglycerol Production Mediated by Phosphatidylcholine-Specific Phospholipase C (1993) (2)
In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay (1987) (2)
[Platelet aggregation and coenzyme Q10 content in platelets in cancer patients]. (1984) (2)
[Cell cycle regulation by anticancer agent]. (1995) (2)
4001 ORAL Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer – a Phase III Trial of the Japan Clinical Oncology Group (JCOG0301) (2011) (2)
Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics/Pharmacodynamics Study (2007) (2)
Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. (2003) (2)
Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay (2004) (2)
Overcoming drug resistance in lung cancer. (1997) (2)
[Developed new agents for lung cancer]. (2002) (2)
[In vitro antitumor activity of 7-N-(p-hydroxyphenyl)-mitomycin C (KW-2083) against cultured bronchogenic carcinoma cells (PC-7)]. (1983) (2)
Erratum to “Detection of unsuspected distant metastates and/or regional nodes by FDG-PET scan in apparent limited-disease small-cell lung cancer” [Lung Cancer 57 (2007) 328–333] (2007) (2)
Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology Group. (1998) (2)
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials (2004) (2)
Chronopharmacology of etoposide given by low dose prolonged infusion in lung cancer patients. (1997) (2)
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510. (2009) (2)
Preliminary phase II study of adriamycin (ADM) in patients with non-small cell lung cancer (NSCLC). (1985) (2)
[Effect of CDDP administration on NK activity of human peripheral lymphocytes and its modification by corticosteroid as anti-emetic agent]. (1984) (1)
Calcitriol increases adriamycin sensitivity in human non-small cell lung cancer cells (1993) (1)
[Role of asialo GM 1 positive cells in the control of metastatic spread of tumor cells in mice]. (1983) (1)
The different effects of recombinant human tumor necrosis factor on rat fibrosarcoma sublines (2004) (1)
[Evidence based chemotherapy for lung cancer]. (2000) (1)
Basic Treatment Strategies for Lung Cancer (2003) (1)
Characterization and Mechanism of Resistance Cell Line of Human Non-Small Cell Lung Cancer : Establishment of a Camptothecin Analogue ( CPT-11 )-resistant (2006) (1)
[Significance of the bioclean room during the treatment of lung cancer]. (1984) (1)
Impact of Serum HGF on Treatment Response to EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Adenocarcinoma (2010) (1)
[Multidisciplinary treatment for small cell lung cancer]. (1984) (1)
In Vitro and In Vivo Cytogenetic Effects of Recombinant Interleukin‐2 on Human Lymphocytes (1994) (1)
D1-04: Cisplatin (Cis) + etoposide (VP16) vs. cis + irinotecan (CPT11) in extensive stage small cell lung cancer (E-SCLC): Updated pharmacogenomic (SWOG 0124) and comparative toxicity analysis (JCOG 9511 & SWOG 0124) (2007) (1)
Trends in demographics and survival for patients (pts) with advanced non-small cell lung cancer (NSCLC). (2006) (1)
A phase II trial of paclitaxel plus carboplatin in patients with non-small cell lung cancer previously treated with chemotherapy. (2006) (1)
[Problems and prospects for combined chemotherapy with 5-fluorouracil and low-dose cisplatin]. (1999) (1)
Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A). (2021) (1)
[Randomized control study of methylprednisolone in the prevention of CDDP-induced emesis]. (1984) (1)
Clinical outcome of chemoradiotherapy in patients (pts) with limited-disease small-cell lung cancer (LD-SCLC) with ipsilateral pleural effusion (2008) (1)
Gastrin-releasing Peptide as a Specific Tumor Marker in Patients with Small Cell Lung Carcinoma 1 (2006) (1)
3066 POSTER Erythropoiesis-stimulating Agents for the Treatment of Chemotherapy-induced Anemia and Mortality: a Meta-analysis of Individual Patient Data From Japanese Randomized Trials (2011) (1)
A case of small cell lung cancer successfully treated with VM26. (1986) (1)
Is radiotherapy optimally combined with chemotherapy in elderly patients with limited-stage small-cell lung cancer? (2005) (1)
Problems with registration-directed clinical trials for lung cancer in Japan. (2007) (1)
Association of SNPs in ABCC1 gene with overall survival in stage IV pancreatic adenocarcinoma patients treated with gemcitabine monotherapy (2008) (1)
Randomized phase III study comparing etoposide and cisplatin (EP) with irinotecan and cisplatin (IP) following EP plus concurrent accelerated hyperfractionated thoracic radiotherapy (EP/AHTRT) for the treatment of limited-stage small-cell lung cancer (LD-SCLC): JCOG0202. (2012) (1)
Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC). (2010) (1)
Toxicity and supportive care in small cell lung cancer: a consensus report (1989) (1)
Report from the second Japanese Urological Association–Japanese Society of Medical Oncology joint conference, 2007: ‘Diagnosis and treatment of urological malignant tumors: How can we promote subspecialists?’ (2008) (1)
Trends in metastatic sites and survival for patients (pts) with stage IV lung cancer (2008) (1)
Identification of prognostic biomarkers for gastric cancer by gene expression analysis (2007) (1)
[History of cancer chemotherapy; from cytotoxic drugs to molecular targeted therapy]. (2012) (1)
Natural killer (NK) and lymphokine-activated killer (LAK) cell activity in healthy volunteers with special emphasis on the familial incidence of cancer. (1985) (1)
508 POSTER Association of genetic polymorphisms with survival in Japanese pancreatic cancer patients treated with gemcitabine (2007) (1)
Interstitial lung disease associated with amrubicin in the treatment of patients with small cell lung cancer. (2016) (1)
A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2. (2009) (1)
Heregulin as a novel cetuximab-resistace factor in colorectal cancer. (2010) (1)
9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (2009) (1)
Cytolotic activity of natural killer and lymphokine-activated killer cells against human tumor cell lines resistant to chemotherapeutic agents (1993) (1)
Tumor response category for the indicator of prognosis: Analysis of survival data in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC). (2009) (1)
O-278 Randomized phase II study of cisplatin (P), irinotecan (I), and etoposide (E) combinations administered weekly or every four weeks for extensive small cell lung cancer (ESCLC): JCOG9902-DI (2003) (1)
ZD6474 (ZACTIMA™), a novel inhibitor of VEGF receptor-2 tyrosine kinase, inhibits cellular growth of mesothelioma cell lines in vitro (2006) (1)
[Preclinical trials from the standpoint of clinical trials]. (1991) (1)
Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro. (2002) (1)
[In vitro drug sensitivity test]. (1987) (1)
Impact of cytidine deaminase genetic polymorphisms on gemcitabine kinetics and toxicity in Japanese cancer patients (2005) (1)
Phase I/II trial of cisplatin (CDDP), etoposide (ETP), and irinotecan (CPT-11) for the treatment of advanced non-small-cell lung cancer (NSCLC). Japan Clinical Oncology Group (JCOG) study 9512 (2000) (1)
Biological basis of combined therapy (1994) (1)
The analysis of cytostatic activity of human peripheral blood granulocytes and its augmentation with Nocardia rubra cell wall skeleton (N-CWS) (2004) (1)
Dose intensive chemotherapy for limited-stage (LS) small cell lung cancer (SCLC): A phase II study (2005) (1)
Final overall survival results of a randomized phase III trial comparing weekly docetaxel plus cisplatin (DP) with 3-weekly docetaxel (D) monotherapy in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC): intergroup trial JCOG0803/WJOG4307L. (2015) (1)
[Analyses of the natural killer activities of human peripheral blood lymphocytes from normal volunteers and from patients with primary lung cancer and with metastatic pulmonary tumors (author's transl)]. (1980) (1)
[Safety and efficacy of docetaxel in prostate cancer patients: based on the post-marketing surveillance in Japan]. (2012) (1)
[Phase I-II study of recombinant interleukin-2]. (1987) (1)
Y/6 chromosome translocation in a male with triple primary cancers involving the breast (2005) (1)
Validation study of direct sequencing and PCR-invader for detecting EGFR mutations in non-small cell lung cancer (NSCLC). (2009) (1)
Prognostic factors for response and survival of second-line chemotherapy in patients with relapsed small cell lung cancer (SCLC) (2007) (1)
[Current perspectives in the management of small cell lung cancer]. (1985) (1)
Cross-resistance to antineoplastic agents in a human small-cell lung-cancer subline resistant to okadaic Acid. (1995) (1)
[Cancer screening]. (2005) (1)
A phase I/II study of pemetrexed plus cisplatin in Japanese patients with malignant pleural mesothelioma (2007) (1)
Treatment of Malignant pleural Effusions and Its Effect on the Survival of patients (1978) (1)
Preliminary Phase II Study of 1-(2-Chloroethyl)-3-(MethylAlpha-D-Glucopyranos-6-Yl)-1-Nitrosourea (MCNU) Against Primary Lung Cancer and Metastatic Pulmonary Tumors (1982) (1)
P-529 Combination phase I study of paclitaxel and nedaplatin (254-S) in patients with unresectable squamous cell carcinoma (2003) (1)
[Essential conditions for the development of new anticancer drugs based on ICH-GCP]. (1998) (1)
426PDEfficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC (2015) (1)
[Selection of drugs for chemotherapy based on drug resistance marker]. (1996) (1)
The suppressive effect of macrophages activated with interferon-γ and lipopolysaccharide on the colony formation of P388 and its drug-resistant cell lines (1991) (1)
[Analysis of the mechanism of cancer metastasis by using anticancer agents]. (1984) (1)
Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers. (2002) (1)
Correlation between total dose of cisplatin and vibratory perception thveshold in chemotherapy-induced peripheral neuropathy of cancer patients (1992) (1)
Genetic polymorphisms correlate with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX) (2008) (1)
[Chemotherapy against pulmonary metastasis from uterine cervical carcinoma]. (1982) (1)
[Current perspectives in the management of non-small cell lung cancer]. (1985) (1)
1079 A phase II trial of chemoradiotherapy followed by surgery in pancoast tumors: Initial report of the Japan Clinical Oncology Group trial (JCOG 9806) (2003) (1)
Effect of Combined Chemotherapy with Lysosome Labilizers and Mitomycin-C (1976) (1)
Current trend in incidence of severe interstitial lung disease (ILD) due to gefitinib in Japan. (2009) (1)
Five-year follow-up of preoperative chemotherapy (Cx) of docetaxel with or without cisplatin for clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Report of a Japan Clinical Oncology Group study (JCOG0204). (2010) (0)
Guideline for clinical safety data management in Japan Clinical Oncology Group (JCOG) (version 4) (2001) (0)
46 Phase I study of oral platinum (PT) ANALOG JM-216 given daily for 5 days☆ (1997) (0)
PL 04.02 Where We Are Now, and Where We Will Be in 10 years: From Asian Perspective (2017) (0)
[Fundamental study and clinical testing of human tumor clonogenic assay (HTCA)]. (1986) (0)
P-560 Phase I-II study of amrubicin and cisplatin as first-line treatment in patients with extensive stage small cell lung cancer (ED-SCLC) (2003) (0)
[The value of carcinoembryonic antigens in patients with advanced lung cancer: in relation to chemotherapy]. (1984) (0)
A new antitumor antibiotic FR66973: clonogenic in vitro assessment of activity against human non-small cell lung carcinoma (1987) (0)
Lower recommended dose but not diminished efficacy obtained in elderly patients age 75 years or older in phase I study of cisplatin and docetaxel administered by 3 consecutive weekly infusions for advanced non-small cell lung cancer (2000) (0)
PL05.04: Translational Lung Cancer Research (2017) (0)
act of Serum Hepatocyte Growth Factor on Treatment ponse to Epidermal Growth Factor Receptor Tyrosine ase Inhibitors in Patients with Non–Small Cell (2010) (0)
P-218 A phase II study of cisplatin and docetaxel administered as 3 consecutive weekly infusions for advanced NSCLC in elderly patients (2003) (0)
[Globalization of anti-cancer therapies]. (2002) (0)
What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer? (2005) (0)
303 Phase II study of alternating radiotherapy (RT) and chemotherapy (CT) for locally advanced non-small-cell lung cancer (NSCLC). JCOG study 9306 (1997) (0)
E53. Preclinical and clinical studies of molecular target-based drugs in Japan (2005) (0)
Contents Vol. 34, 2016 (2016) (0)
Survival of Resected and Non-resected Cases of Metastasis from Uterine Cancer in Relation to Chemotherapeutic Effects (1981) (0)
[Bioassay of cis-diamminedichloroplatinum (II) by human tumor clonogenic assay]. (1984) (0)
The development of a treatment model for lymph node metastasis in nude mice transplanted with rat fibrosarcoma clone A. (1991) (0)
89 Relationship between GST-π Gene Expression and Cisplatin Resistance in Lung Cancer Cells. Natl. Cancer Cent. (1988) (0)
Target-based anti-cancer drugs (2004) (0)
Summary of the ASCO-JSCO Joint Symposium (2004) (0)
Correlation between total dose of cisplatin and vibratory perception threshold in chemotherapy-induced neuropathy of lung cancer patients (1991) (0)
Highlights for ESMO 40: celebration review for lifetime achievement awards (2016) (0)
Clinical Trials for Lung Cancer in Progress in Japan (2006) (0)
Cisplatin sensitivity and resistance in lung cancer (1998) (0)
Difference of binding-affinity for gefitinib between wild type EGFR and a mutant EGFR (2007) (0)
The efficacy of MVP (mitomycin C, vindesine and cisplatin) regimen as a salvage chemotherapy for non-small cell lung cancer (2000) (0)
[Academism and commercialism with development of new anticancer agents]. (1998) (0)
Randomized phase II trial of irinotecan plus cisplatin (IP) versus irinotecan, cisplatin plus etoposide (IPE) every three weeks in patients with extensive disease small cell lung cancer (ED-SCLC). (2016) (0)
Immunotherapy by intra-peritoneal intra-peritoneal injection of interleukin-2 gene transduced ling cancer cell line. (1994) (0)
[An overview of new prognostic factors in lung cancer]. (1992) (0)
[The changes in serum neuron-specific enolase in patients with small cell lung cancer]. (1987) (0)
[Expectations in the clinical application of human-recombinant cytokines. 2) Clinical trials of IL-2]. (1988) (0)
[Strategies for the overcoming of drug resistance]. (1995) (0)
Phase I study of docetaxel (DTX) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC) (2000) (0)
Drug resistance in lung cancer: Topoisomerases as determinants of chemosensitivity (1997) (0)
Phase I Study of Combination Therapy with Interleukin 2 and ^-Interferon in Patients with Advanced Malignancy1 (2006) (0)
An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma. (2011) (0)
Reversal of cisplatin-resistance by 1,4-benzothiazepin derivative, JTV-519 (2000) (0)
IS7. lung cancer (2012) (0)
[The strategy of combination phase I/II study]. (2000) (0)
Pharmacokinetics of cisplatin and combination chemotherapy of cisplatin plus 5-FU. (1998) (0)
Differences in cellular proteins between high and low metastatic potential sublines from the methylcholanthrene-induced rat fibrosarcoma cell line. (1992) (0)
CORRECTION (2001) (0)
Antiemetic therapy. (1999) (0)
A case report of adenocarcinoma of the lung in which a partial response was achieved by carboplatin. (1987) (0)
Evaluating NSCLC Treatment Options Using Real World Data: Findings from an Oncology Survey Across Eight Countries (2018) (0)
Concurrent cisplatin/etoposide (PE) and twice-daily thoracic radiotherapy (BID TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC) (2000) (0)
Enhancement of Epidermal Growth Factor Receptor-degradation Pathway in Acquired Gefitinib-resistant Human Non-small Cell Lung Cancer Cell Lines (2004) (0)
Is cisplatin necessary for the treatment of non-small cell lung cancer (NSCLC)? — Analysis of consecutive trials of paclitaxel in NSCLC (2000) (0)
Mutational analysis of EGFR and KIT in thymic epithelial tumor (2007) (0)
Phase II Study of 3-Hour Infusion of Paclitaxel in Previously Untreated Non-Small Cell Lung Cancer 1 (2005) (0)
[Cyclosporine as drug resistance modifiers; mechanism and clinical investigation]. (1997) (0)
556 Ectopic p16INK4 expression enhances the susceptibility of human non-small cell lung cancer (NSCLC) cells to CPT-11-induced apoptosis (1997) (0)
A randomized trial of intrapericardial (ip) bleomycin (BLM) after drainage for management of malignant pericardial effusion (MPE) in lung cancer patients (pts): Report of a Japan Clinical Oncology Group trial (JCOG 9811) (2007) (0)
[Present status and educational training for medical oncologist in Japan]. (1997) (0)
[Cis-dichlorodiammine platinum (II) CDDP in the treatment of non-small cell lung cancer]. (1984) (0)
Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients with chemotherapy-induced anemia. (2004) (0)
Abstract 2296: Sorafenib inhibits hepatocyte growth factor-induced epithelial mesenchymal transition in hepatocellular carcinoma (2010) (0)
[Vibratory perception threshold in normal volunteers]. (1994) (0)
Effect of suramin on cdc2 kinase activity of the purified enzyme and from the crude extracts from lung cancer cells (1994) (0)
Eighteen cases of malignant mediastinal tumor treated with chemotherapy. (1990) (0)
Meeting Report of the Seventh IASLC Lung Cancer Biology Workshop: Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer, Barcelona, Spain, April 30- May 3, 2001. (2001) (0)
Randomized Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (EP/AHTRT) for the Treatment of Limited-Stage Small-Cell Lung Cancer (LD-SCLC): JCOG0202 (2012) (0)
Common arm comparative outcomes analysis of phase III trials of cisplatin + irinotecan vs. cisplatin + etoposide in extensive stage small cell lung cancer: Final patient-level results from JCOG 9511 and SWOG 0124 (2011) (0)
Inhibitory effects of repeated intravenous injections of dexamethasone on pulmonary toxicity of a new mitomycin C analogue, KW-2149, in a novel rat model. (2000) (0)
Can dose-dense chemotherapy improve outcome in patients with better-prognosis small-cell lung cancer? (2005) (0)
Re: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. (2003) (0)
[Effect of 7-N-(P-hydroxyphenyl)-mitomycin C (KW-2083) against pleuritis carcinomatosa]. (1984) (0)
[Therapy for lung cancer in view of internal medicine]. (1993) (0)
Elucidation of the gefitinib (‘Iressa’, ZD1839)-resistant mechanisms in acquired gefitinib-resistant human non-small-cell lung cancer cell lines (2004) (0)
Population differences in the use of EGFR-targeted agents. (2008) (0)
[Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells]. (1986) (0)
Efficacy and Safety ofTwo Doses of Pemetrexed Supplemented with Folic Acid andVitamin B 12 in PreviouslyTreated Patients with Non-Small Cell Lung Cancer (2008) (0)
Abstract 1900: HSP 70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cells that expressed mutant EGFR (2012) (0)
HSP70 Causes EGFR-Tkis Resistance in a Mutant EGFR Expressed Non-Small-Cell Lung Cancer (2012) (0)
Clinical features and the results of treatment of brain metastases in small cell lung cancer. (1990) (0)
Verification of Positron Emitter Nuclei Generated in Human Body by Proton Irradiation (2008) (0)
A prognostic factor risk index in advanced non-small cell lung cancer (NSCLC) treated with combination chemotherapy including cisplatin (1991) (0)
Clinical experiences with platinum and etoposide therapy in lung cancer. (1992) (0)
[Doctor-initiated clinical trials and the revised pharmaceutical affairs law]. (2003) (0)
Clinical Molecular Biology of Pulmonary of Lung Cancer (1992) (0)
[Immunotherapy and immunochemotherapy of neoplasms-- present status and prospects]. (1981) (0)
Contents, Supplement 1, 1992 (1992) (0)
[The present status and prospects for clinical oncology in Japan]. (1994) (0)
[Trastuzumab for treatment of advanced breast cancers]. (2000) (0)
[The introduction of new drugs from the basic research to clinical application--issues in the drug development]. (1994) (0)
9069 A risk–benefit analysis according to age using pooled data from two phase II trials of cisplatin plus S-1 for non-small-cell lung cancer in Japan (2009) (0)
Treatment for small cell lung cancer--present status and future prospects. (1988) (0)
and Pharmacodynamics of Paclitaxel: A 3-Hour Infusionversus a 24-Hour Infusion' (1995) (0)
What is the most informative pharmacodynamic model for paclitaxel (T)? : a 3 hour-infusion vs. 24-hour infusion. (1994) (0)
Clinical predictive factors for mutations in epidermal growth factor receptor (EGFR) exon 19 and 21 in Japanese patients with lung cancer (2007) (0)
[Cancer prevention]. (2005) (0)
[Effect of C-reactive protein on natural killer activity]. (1983) (0)
[Immunosuppressive drugs and the lymphocytes]. (1969) (0)
[cis-Dichlorodiammine platinum (II) in the treatment of advanced colo-rectal cancer]. (1985) (0)
585 Enhanced sensitivity to cisplatin in high mobility group 2 (HMG2) gene-transfected cells (1997) (0)
Monitoring serum KL-6 as a useful marker for radiation pneumonitis (2000) (0)
Second IASLC Workshop on Combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Biological basis of combined therapy. (1994) (0)
Correlation B etween D ocetaxel C learance a nd E stimated Cytochrome P 450 A ctivity b y U rinary M etabolite o f Exogenous C ortisol (2000) (0)
Augmentation of colony formation of cultured cell lines by pleural effusion from patients with lung cancer. (1988) (0)
Once weekly epoetin beta to increase hemoglobin and improve quality of life in anemic cancer patients receiving chemotherapy: A randomized, double-blind, dose-finding study. (2004) (0)
Abstract 1209: Detection of EGFR T790M mutation in non-small-cell lung cancer patients using colony hybridization assay (2012) (0)
Strategies and problems of gene therapy of cancer. (1995) (0)
Drug Accumulation and Efflux Do not Contribute to Acquired Gefitinib Resistance (2009) (0)
Upregulated gene expression of angiogenesis factors in post-chemotherapeutic resected lung cancer tissues determined by cDNA macroarray (2000) (0)
[Efficacy of chest CT on the staging and re-staging in patients with small cell lung cancer]. (1990) (0)
Alerance mechanisms of drug resistance in human lung cancer (1997) (0)
[Treatment with antiangiogenic drugs]. (2010) (0)
45 Clinical significance of re-operation for recurrent non-small celllung cancer (2005) (0)
556 Pilot combination phase II study of Carboplatin (CBDCA) and Etoposide (VP-16) for small cell lung cancer. (1988) (0)
Antitumor activity of radiation therapy in patients with non-small cell lung cancer refractory to vindesine + cisplatin therapy (1989) (0)
Clinical significance of ABC transporter and DNA excision repair protein expressions in small-cell lung cancer (SCLC) patients (2008) (0)
[Chemotherapy for small cell lung cancer]. (1988) (0)
[Effect of chemotherapy on anticancer immune effector cells]. (1983) (0)
Differences of lysosomal membranes stabilities recognized between tumor cells and non-tumor cells against lysosome labilizers. (1976) (0)
[gamma-Glutamylcysteine synthetase and chemosensitivity]. (1997) (0)
Identification of prognostic factors for patients with advanced pancreatic cancer by proteomics. (2009) (0)
[Issues in cancer treatments--EBM, individuation, and standardization]. (2001) (0)
[Direct and indirect antitumor effect of murine recombinant interferons]. (1987) (0)
O-155 Randomized phase III trial of carboplatin (Cb) or cisplatin (P) in combination with etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): Report of a Japan Clinical Oncology Group Trial (JCOG9702) (2005) (0)
A cationic liposomal gene delivery system with adenoviral DNA-terminal protein complex (2000) (0)
Analysis of optimal timing of gefitinib in sensitive non-small cell lung cancer (NSCLC) patients: Should we use gefitinib as first-line chemotherapy? (2009) (0)
A Phase III Study Comparing Amrubicin and Cisplatin (AP) with Irinotecan and Cisplatin (IP) for the Treatment of Extended-Stage Small Cell Lung Cancer (ED-SCLC): JCOG0509 (2012) (0)
Taxane-platinum pharmacogenomic predictors of outcome in Japan-USA common arm studies in advanced non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics: M08-01 (2007) (0)
Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy. (2009) (0)
[The palliative care in the clinical oncology]. (2007) (0)
CPT-11 shifts a circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver (2000) (0)
9134 POSTER Tumour Response, Skin Rash and Health-related Quality of Life (HRQoL) – Post-hoc Data From the IPASS Study (2011) (0)
A phase II trial of zoledronic acid in combination with cisplatin and docetaxel in non-small cell lung cancer patients with bone metastases. (2010) (0)
P-247 FLOW CYTOMETRIC MONITORING OF CELLULAR DOXORUBICIN RETENTlON AND ITS HETEROGENEITY IN DRUG RESISTANT HUMAN LUNG CANCER CELL LINES (1992) (0)
Future prospects for the treatment of non small cell lung cancer (2001) (0)
P-875 Is surgical resection indicated for solitary NSCLC recurrence? (2005) (0)
Bayesian Estimation for TDM of Anticancer Drugs: Evaluation of Different Population Methods (1996) (0)
[Present status and future prospects of antibody therapy against solid tumor]. (2012) (0)
Treatment of Small Cell Lung Cancer. (2003) (0)
PD-050 A phase II trial of pre-operative chemoradiotherapy followedby surgical resection in Pancoast tumors: Report of a Japan Clinical Oncology Group trial (JCOG 9806) (2005) (0)
[Effects of recombinant human colony stimulating factor (rh-CSFs) on colony formation of lung cancer cell lines]. (1989) (0)
142 Cisplatin plus oral etoposide in the treatment for patients with advanced small cell lung cancer (1997) (0)
19.Endpoints for multimodol clinical trials in stage III NSCLC(第108回日本肺癌学会関東支部会) (1994) (0)
Meeting report of the 74th Congress of the Japanese Gastric Cancer Association (2002) (0)
[A mechanism of cisplatin resistance in a cisplatin resistant lung cancer cell line]. (1990) (0)
[Strategy of therapy for lung cancer]. (2002) (0)
[The meaning and prospect of chemosensitivity tests]. (1989) (0)
[Randomized systemic chemotherapy using two or three drug combination for small cell lung cancer (SCLC)]. (1984) (0)
[Growth factor induced signal transduction in lung cancer]. (2002) (0)
Effect of BCG on cytostatic activity of peritoneal macrophages from normal and tumor-bearing rats. (1979) (0)
Abstract A182: PI3K inhibitors overcome resistance to HER2‐targeted agents caused by PIK3CA mutations in HER2‐amplified breast cancer cell lines (2009) (0)
Trends in chemotherapy for elderly patients with non-small cell lung cancer: The experience of one institution. (2009) (0)
Phase I Study of a Weekly Infusion of Irinotecan Hydrochloride (CPT‐11) and a 14-day Continuous Infusion of Etoposide in Patients with Lung Cancer: Japan Clinical Oncology Group 9408 (2000) (0)
Comment on: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. Authors' reply (2003) (0)
Abstract 3313: Snail and slug-mediated epithelial mesenchymal transition in lung cancer cells (2010) (0)
Comparison of unidimensional and bidimensional measurement for evaluating tumor response to chemotherapy in patients with non-small cell lung cancer (NSCLC) (2000) (0)
Gb-7 Pharmacokinetic (PK) interpatient variability of CPT-11 (1991) (0)
M08-02: Topoisomerase I inhibitors (2007) (0)
[Augmentation of the cytostatic activity of granulocytes by biological response modifiers (BRM)]. (1983) (0)
Weekly paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC) (2005) (0)
[International estimation of molecular target drug]. (2004) (0)
Discussion: Evaluation of Current Clinical Status and Future Directions in Small Cell Lung Cancer (1992) (0)
[Molecule based diagnosis]. (2004) (0)
Abstract 699: HSP70 specifically binds to 15 bp deletion mutant EGFR and modulates sensitivity to EGFR-TKI (2011) (0)
[The role of the Japan Clinical Oncology Group]. (2000) (0)
[Phase II clinical trials in patients with lung cancer]. (1993) (0)
[Analyses of antitumor effects of mononuclear cells and the future prospects of immunotherapy]. (1985) (0)
[Progress in the management of vomiting associated with antineoplastic agents]. (1985) (0)
[Clinical application of human recombinant colony stimulating factor]. (1989) (0)
[The control of chemotherapy-induced nausea and vomiting]. (1985) (0)
Cancer Cell Lines : Relation to DNA Damage and Repair-Diamminedichloroplatinum ( II ) in Human Non-Small Cell Lung cis Decreased Accumulation as a Mechanism of Resistance to Updated (2006) (0)
Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant (2012) (0)
[Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group]. (1985) (0)
Rationale for the combination therapy of 5FU and CDDP. (1993) (0)
BiomarkerAnalysesandFinalOverallSurvivalResultsFroma PhaseIII,Randomized,Open-Label,First-LineStudyofGefitinib VersusCarboplatin/PaclitaxelinClinicallySelectedPatientsWith AdvancedNon-Small-CellLungCancerinAsia(IPASS) (2011) (0)
93 Are the Human Lung Cancer Cell Lines Useful to Screen Effective Agents against Lung Cancer (1988) (0)
The effect of pain on survival in non-small cell lung cancer (NSCLC) patients with bone metastases receiving chemotherapy (2008) (0)
[Effect of peripheral blood lymphocytes on in vitro colony formation of human lung cancer cell line (PC-7)]. (1984) (0)
[Ideal of multicenter clinical trials--the scientific and ethical aspects--clinical trials on cancer]. (1997) (0)
[Stem cell assay of neoplastic cells]. (1986) (0)
P-460 Inter-observer variability in tumor response evaluation according to RECIST (Response Evaluation Criteria in Solid Tumors) guidelines (2003) (0)
134 Correlation between CDDP Resistance and The Expression of Glutathione S-Transferase-π Gene in Ovarian Cancer Cell Lines. (1989) (0)
[Medical oncology in Japan]. (2002) (0)
222 17-AAG, an inhibitor of HSP90, suppresses cellular growth of mesothelioma cell lines in vitro (2006) (0)
[Treatment guideline for advanced or recurrent breast cancer]. (2000) (0)
Abstract 3424: Slug-mediated epithelial mesenchymal transition in lung cancer cells (2011) (0)
Ideal way of multicenter clinical trial - science and ethics. Clinical trial of cancer therapy. (1997) (0)
SNP Communication Genetic Variations and Haplotype Structures of the Glutathione S-transferase Genes , GSTT 1 and GSTM 1 , in a Japanese Patient Population (2009) (0)
Inhibitory effects of dexamethasone on pulmonary toxicity of a new mitomycin C analogue KW-2149 in a novel rat model. (1998) (0)
[Combination therapy of targeted drugs]. (2012) (0)
[The role of chemotherapy in metastatic pulmonary tumors in a disease-oriented phase II study of anticancer agent]. (1985) (0)
A phase I trial of cisplatin (CDDP), docetaxel (DCT) and ifosfamide (IFX) in advanced non-small cell lung cancer (NSCLC) (2000) (0)
P-874 Clinical significance of surgical resection for recurrent non-smallcell lung cancer (2005) (0)
[Chemotherapy for non-small cell lung cancer]. (1996) (0)
A trial of chemotherapy for lung cancer in short-term hospitalization. (1986) (0)
Correction. (2016) (0)
[Chemosensitivity test for lung cancer]. (1990) (0)
[Preliminary phase II study of cis-Dichlorodiammineplatinum (II) in patients with non-small cell carcinoma of the lung and metastatic pulmonary tumor]. (1984) (0)
[Growth factor and signal transduction in lung cancer cell]. (2000) (0)
Enhanced apoptotic response to photodynamic therapy after IL-6 transfection (2000) (0)
Efforts in Lung Cancer : Focus on Early-Stage Non – Small-Cell Lung Cancer comprehensive review (2011) (0)
Antitumor activity of TZT-1027 against cytokine-gene-transfected Lewis lung carcinomas inoculated to C57BL/6 mice (2000) (0)
548 POSTER Active mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl ubiquitin ligase (2006) (0)
[Clinical phase II study of K-18 in cancer of the digestive organs]. (1988) (0)
COOPERATIVE RANDOMIZED STUDY OF THE TREATMENT OF SMALL CELL LUNG CANCER(SCLC) (1989) (0)
Antitum or Activity of O xaliplatin, 5-FU and Paclitaxel G iven Alone or in Com bination with ZD 1839 in H um an Gastric Carcinom a Cells in vitro (2003) (0)
Summary of the ASCO–JSCO Joint Symposium (2004) (0)
A case of adenocarcinoma of the lung which was successfully treated by chemotherapy with patient survival without recurrence for more than three years. (1987) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nagahiro George Saijo?

Nagahiro George Saijo is affiliated with the following schools: